Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A team of researchers recently cross-tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies to assess their neutralization activity against different variants. The team recently released their findings as a preprint on the medRxiv* server.

20 May 2021

SARS-CoV-2 variant spread study in France shows B.1.351/V2 variant outgrowing B.1.1.7/V1 variant

A recent study by researchers in France has compared the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. The team found a significant transmission advantage of V2 (from lineage B.1.351) over V1 (from lineage B.1.1.7). A pre-print version of the research paper is available on the medRxiv* server.

20 May 2021

Stark racial disparities persist in vaccinations, state-level CDC data shows

Black Americans’ covid-19 vaccination rates are still lagging months into the nation's campaign, while Hispanics are closing the gap and Native Americans show the highest rates overall, according to federal data obtained by KHN.

20 May 2021

Despite pandemic, Newsom declines to boost local public health budgets — again

In spite of a pandemic that has killed about 62,000 Californians — more than enough to pack Dodger Stadium — Gov. Gavin Newsom has again declined to boost the budgets of the state's underfunded and understaffed local public health departments.

20 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Researchers tested the vaccine candidate in mice with up to three doses and found it produces high levels of antibodies against both SARS-CoV-2 variants of concern and the original virus strain.

20 May 2021

Two new SARS-like coronaviruses described in Russian horseshoe bats

Horseshoe bats (Rhinolophus sp.) are known reservoirs of zoonotic coronaviruses (CoVs). Over the last twenty years, viruses thought to have originated from these bats have given rise to two severe acute respiratory syndrome (SARS) epidemic outbreaks in humans: SARS-CoV-1 in 2002/2003, which was limited mostly to Asia, and the currently globally circulating SARS-CoV-2, first identified in December 2019.

20 May 2021

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

A new research paper posted to the preprint server medRxiv* reports the rise of a new lineage in Tokyo, Japan, bearing a combination of two biologically important mutations.

20 May 2021

Are COVID-19-related complications in children explained by abnormal immune responses?

A common theme in reports on COVID-19 around the world has been the large number of children who have not been infected or shown signs of disease. However, though the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes less acute infection in this age group, it is associated with a severe immune-mediated multisystemic illness called multisystem inflammatory syndrome in children (MIS-C).

20 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

FDA reminds the public about the limitations of COVID-19 antibody

The following quote is attributed to Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health.

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Researchers at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center found that monoclonal antibodies, a COVID-19 treatment administered early after infection, reduce the risk of hospitalization and death by 60 percent in people at high risk of suffering complications from the condition.

20 May 2021

Study confirms that human endocrine system is strongly involved in SARS-Cov-2 infection

The endocrine system is strongly involved in SARS-Cov-2 infection - so much so that evidence of an "endocrine phenotype" of COVID-19 has emerged, according to a statement by the European Society of Endocrinology (ESE) published in the journal Endocrine in April 2021.

20 May 2021

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Researchers in the UK have demonstrated the efficacy of the Pfizer-BioNTech and AstraZeneca vaccines against severe acute respiratory virus coronavirus 2 (SARS-CoV-2) at preventing death among older individuals with coronavirus disease 2019 (COVID-19).

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

The effects of SARS-CoV-2 vaccination on pregnancy and birth

The severe impact of this infection has given rise to a study by Theiler et al. (2021), which investigated the effects of SARS-CoV-2 vaccination in pregnancy in order to examine the protection it could provide to combat the infection.

19 May 2021

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Researchers from the US recently assessed if severe COVID-19 is linked to procoagulant dysfunction of the endothelium and changes in the Tie2-angiopoietin axis. They assessed circulating endothelial markers in a study cohort of 98 patients with mild, moderate, or severe COVID-19. This study is published on the medRxiv* preprint server.

19 May 2021

Working conditions and non-workplace factors affect COVID-19 mortality in England

Researchers from England recently estimated occupational variations in COVID-19 mortality in England and Wales during 2020 and examined how these differences changed post adjustment for non-workplace factors.

19 May 2021

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Researchers from Israel recently isolated a set of SARS-CoV-2 neutralizing monoclonal antibodies from blood samples of patients with severe COVID-19. They were the first to show that transgenic K18-hACE2 mice infected with lethal doses of SARS-CoV-2 can be fully protected by administering antibodies even 3 days after infection

19 May 2021

Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

SARS-CoV-2 variant spread study in France shows B.1.351/V2 variant outgrowing B.1.1.7/V1 variant

Stark racial disparities persist in vaccinations, state-level CDC data shows

Despite pandemic, Newsom declines to boost local public health budgets — again

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Two new SARS-like coronaviruses described in Russian horseshoe bats

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

Are COVID-19-related complications in children explained by abnormal immune responses?

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

FDA reminds the public about the limitations of COVID-19 antibody

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Study confirms that human endocrine system is strongly involved in SARS-Cov-2 infection

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

The effects of SARS-CoV-2 vaccination on pregnancy and birth

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Working conditions and non-workplace factors affect COVID-19 mortality in England

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Newsletters you may be interested in